You are about to leave a GSK website. By clicking this link, you will be taken to a website that is independent from GSK. The site you are linking to is not controlled or endorsed by GSK, and GSK is not responsible for the content provided on that site.
The people in these videos are advocates for meningococcal disease vaccination. Some were compensated by GSK for their participation. These videos are personal experiences; other people’s experiences with meningococcal disease may be different.
Vaccination may not protect all recipients.
CDC=Centers for Disease Control and Prevention; MenB=meningococcal serogroup B; MenACWY=meningococcal serogroups A, C, W, and Y.
References: 1. Pelton SI. Meningococcal disease awareness: clinical and epidemiological factors affecting prevention and management in adolescents. J Adolesc Health. 2010;46:S9-S15. 2. Thompson MJ, Ninis N, Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. Lancet. 2006;367(9508):397-403. 3.National Meningitis Association. Meningococcal Disease on U.S. College Campuses, 2013-2019. http://www.nmaus.org/wp-content/uploads/2019/04/Alembic_NMA_Map_r28.pdf. Updated April 2019. Accessed March 23, 2020. 4.Centers for Disease Control and Prevention. Meningococcal vaccination for adolescents: Information for healthcare professionals. http://www.cdc.gov/vaccines/vpd/mening/hcp/adolescent-vaccine.html. Updated July 26, 2019. Accessed January 16, 2020.
Trademarks are owned by or licensed to the GSK group of companies.
This website is funded and developed by GSK.
This site is intended for US healthcare professionals only.
The GSK Response Center is available to answer your questions at 1-888-593-5977, Monday-Friday, 8:30 am - 5:30 pm ET.
During the hours the GSK Response Center is not available, please feel free to Contact GSK.